Pediatrix Medical Group upgraded by Jefferies with a new price target
$MD
Hospital/Nursing Management
Health Care
Jefferies upgraded Pediatrix Medical Group from Hold to Buy and set a new price target of $14.00 from $8.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/16/2024 | Outperform | Macquarie | |
| 9/26/2024 | $8.00 → $14.00 | Hold → Buy | Jefferies |
| 6/7/2024 | $8.00 | Sell → Hold | Deutsche Bank |
| 2/23/2022 | $32.00 → $31.00 | Outperform | Credit Suisse |
| 12/22/2021 | $33.00 → $32.00 | Outperform | Credit Suisse |
| 11/4/2021 | $29.00 → $27.00 | Market Perform | SVB Leerink |
| 9/27/2021 | $29.00 | Market Perform | SVB Leerink |
| 8/9/2021 | $30.00 → $32.00 | Neutral | Mizuho |
Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 6, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2025. A detailed press release will be issued the morning of May 6, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited
Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 6, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2025. A detailed press release will be issued the morning of May 6, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
Macquarie initiated coverage of Pediatrix Medical Group with a rating of Outperform
Jefferies upgraded Pediatrix Medical Group from Hold to Buy and set a new price target of $14.00 from $8.00 previously
Deutsche Bank upgraded Pediatrix Medical Group from Sell to Hold and set a new price target of $8.00
SC 13G - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
Executive Chair Mark S. Ordan to Return as Chief Executive Officer Company Redoubles Strategic Focus on Physician Practices and Hospital and Health System Relationships Pediatrix Medical Group, Inc. (NYSE:MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today announced a leadership transition to accelerate its progress in executing a transformational strategy designed to create value for shareholders and other stakeholders. To best position Pediatrix to implement the strategy, which is based on recommitting to the highest standards in clinical excellence and strengthening the Company's hospital relationships, the Company's Board of Directors has appointed Ex
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today announced that its board of directors has appointed Sylvia Young, a recognized leader in healthcare and long-term healthcare executive, as an independent director, effective May 12, 2023. Ms. Young, a veteran of hospital administration since 1985, most recently served as President and CEO of the HCA Continental Division, a multi-state regional healthcare system that is part of Hospital Corporation of America (HCA). Prior to her appointment to the Denver-based Division headquarters, Ms. Young served as President of HCA's Sunrise Health System, inclu
PALM BEACH, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- BurgerFi International, Inc. (NASDAQ:BFI, BFIIW))) ("BurgerFi" or the "Company"), one of the nation's fastest-growing premium fast-casual concepts, has appointed Vivian Lopez-Blanco to its board of directors, effective July 14, 2021. Lopez-Blanco's appointment follows the sudden passing of board member Steven Berrard announced on June 10, 2021. Lopez-Blanco has also been named as the chair of the audit committee and will be serving on the compensation committee and nominating governance committee. Lopez-Blanco is an experienced board member and seasoned finance executive with expertise in organizational transformations and driving prof